News

Filter

Current filters:

Symlin

1 to 9 of 44 results

Amylin's loss deeper on Byetta worries

09-02-2009

Amylin Pharmaceuticals has reported a deepened loss for the year ended December 31, 2008, as sales of…

AmylinByettaExenatide InjectionpramlintideSymlin

Amylin plans restructuring which will lead to $80M reduction in 2009 cash spending

17-11-2008

Having posted disappointing third-quarter results, and seen its share price decline to a six-year low…

Amino AcidsAmylinByettaExenatide InjectionInjectionLillyPhysostigmine SalicylatepramlintideSymlin

Amylin hits 6-year low on Byetta LAR concerns

03-11-2008

Shares in Amylin fell to a six-year low after the US drugmaker on disappointing third-quarter 2008 results…

Amino AcidsAmylinByettaExenatide InjectionInjectionPhysostigmine SalicylatepramlintideSymlin

Amylin's 2nd-qtr 2008 loss widens to $64.8M

04-08-2008

The USA's Amylin Pharmaceuticals says that second-quarter 2008 product sales totaled $200.3 million versus…

Amino AcidsAmylinByettaExenatide InjectionInjectionLillyPhysostigmine SalicylatepramlintideSymlin

Amylin's 1st qtr suffers from low Byetta sales

05-05-2008

The USA's Amylin Pharmaceuticals first-quarter 2008 net loss totaled $68.8 million, or $0.51 per share,…

AmylinByettaExenatide InjectionLillypramlintideSymlin

Amylin's loss for 4th-qtr 2007 worsens 32%

04-02-2008

Higher marketing costs associated with the diabetes drugs Byetta (exenatide) and Symlin (pramlintide…

AmylinByettaExenatide InjectionLillypramlintideSymlin

Amylin's 3rd-qtr net loss narrows to $39.8M

29-10-2007

The USA's Amylin Pharmaceuticals net loss for the quarter ended September 30, 2007, was $39.8 million,…

Amino AcidsAmylinByettaExenatide InjectionInjectionLillyPhysostigmine SalicylatepramlintideSymlin

1 to 9 of 44 results

Back to top